Pasar al contenido principal

IDENTIFICACION DE LOS SUBTIPOS METABOLICOS DE CANCER COLORRECTAL PARA EL DESARROLLO DE MEDICINA PERSONALIZADA

PID2020-115051RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Circulating metabolic markers after surgery identify patients at risk for severe postoperative complications: a prospective cohort study in colorectal cancer

  • Montcusí Ventura, Blanca
  • Madrid-Gambin, Francisco
  • Pozo Mendoza, Óscar J., 1975-
  • Marco, Santiago
  • Marin, Silvia
  • Mayol Girbau, Xavier
  • Pascual, Marta
  • Alonso, Sandra
  • Salvans Ruiz, Silvia
  • Jiménez-Toscano, Marta
  • Cascante Serratosa, Marta
  • Pera Román, Miguel
Background: Early detection of postoperative complications after colorectal cancer (CRC) surgery is associated with improved outcomes. The aim was to investigate early metabolomics signatures capable to detect patients at risk for severe postoperative complications after CRC surgery. Materials and methods: Prospective cohort study of patients undergoing CRC surgery from 2015 to 2018. Plasma samples were collected before and after surgery, and analyzed by mass spectrometry obtaining 188 metabolites and 21 ratios. Postoperative complications were registered with Clavien-Dindo Classification and Comprehensive Complication Index. Results: One hundred forty-six patients were included. Surgery substantially modified metabolome and metabolic changes after surgery were quantitatively associated with the severity of postoperative complications. The strongest positive relationship with both Clavien-Dindo and Comprehensive Complication Index (β=4.09 and 63.05, P <0.001) corresponded to kynurenine/tryptophan, against an inverse relationship with lysophosphatidylcholines (LPCs) and phosphatidylcholines (PCs). Patients with LPC18:2/PCa36:2 below the cut-off 0.084 µM/µM resulted in a sevenfold higher risk of major complications (OR=7.38, 95% CI: 2.82-21.25, P <0.001), while kynurenine/tryptophan above 0.067 µM/µM a ninefold (OR=9.35, 95% CI: 3.03-32.66, P <0.001). Hexadecanoylcarnitine below 0.093 µM displayed a 12-fold higher risk of anastomotic leakage-related complications (OR=11.99, 95% CI: 2.62-80.79, P =0.004). Conclusion: Surgery-induced phospholipids and amino acid dysregulation is associated with the severity of postoperative complications after CRC surgery, including anastomotic leakage-related outcomes. The authors provide quantitative insight on metabolic markers, measuring vulnerability to postoperative morbidity that might help guide early decision-making and improve surgical outcomes. Trial registration: ClinicalTrials.gov NCT02789709., This study was supported by research grant from Instituto de Salud Carlos III (FIS grant PI19/00643) and co-funded by the European Union. FMG was supported by Grant FJC2018-035791-I funded by MCIN/AEI/10.13039/501100011033. SM and MC were supported by Grant PID2020-115051RB-I00 funded by MCIN/AEI/10.13039/501100011033. SM and MC were supported by Grant 2017SGR1033 funded by AGAUR. MC was supported by ‘ICREA Academia’ award funded by ICREA Foundation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes

  • Pedrosa, Leire
  • Foguet, Carles
  • Oliveres, Helena
  • Archilla, Iván
  • García de Herreros, Marta
  • Rodríguez, Adela
  • Postigo, Antonio
  • Benítez-Ribas, Daniel
  • Camps, Jordi
  • Cuatrecasas, Miriam
  • Castells, Antoni
  • Prat, Aleix
  • Thomson, Timothy M.
  • Maurel, Joan
  • Cascante, Marta
Existing immune signatures and tumor mutational burden have only modest predictive capacity for the efficacy of immune check point inhibitors. In this study, we developed an immune-metabolic signature suitable for personalized ICI therapies. A classifier using an immune-metabolic signature (IMMETCOLS) was developed on a training set of 77 metastatic colorectal cancer (mCRC) samples and validated on 4,200 tumors from the TCGA database belonging to 11 types. Here, we reveal that the IMMETCOLS signature classifies tumors into three distinct immune-metabolic clusters. Cluster 1 displays markers of enhanced glycolisis, hexosamine byosinthesis and epithelial-to-mesenchymal transition. On multivariate analysis, cluster 1 tumors were enriched in pro-immune signature but not in immunophenoscore and were associated with the poorest median survival. Its predicted tumor metabolic features suggest an acidic-lactate-rich tumor microenvironment (TME) geared to an immunosuppressive setting, enriched in fibroblasts. Cluster 2 displays features of gluconeogenesis ability, which is needed for glucose-independent survival and preferential use of alternative carbon sources, including glutamine and lipid uptake/β-oxidation. Its metabolic features suggest a hypoxic and hypoglycemic TME, associated with poor tumor-associated antigen presentation. Finally, cluster 3 is highly glycolytic but also has a solid mitochondrial function, with concomitant upregulation of glutamine and essential amino acid transporters and the pentose phosphate pathway leading to glucose exhaustion in the TME and immunosuppression. Together, these findings suggest that the IMMETCOLS signature provides a classifier of tumors from diverse origins, yielding three clusters with distinct immune-metabolic profiles, representing a new predictive tool for patient selection for specific immune-metabolic therapeutic approaches., This study was supported by grants from the Spanish Ministry of Science and Innovation (MICINN) SAF2017-84918-R0 (National Scientific and Technical Research and Innovation 2017–2020 Plan, co-funded by the EUC-ERDF) to APr, PID2019-107139RB-C21 to TT, and PID2020-115051RB-I00 to MCa funded by MCIN/AEI/10.13039/501100011033; grants from Fundació la Marató de TV3 (201330.10) to APo, Foundation Olga Torres (Biannual Grant A-2019/2020) to APo, and Fundació ICREA-Premi Icrea Academia to MCa; grants from Catalan Agency for Management of University and Research Grants (AGAUR) 2017-SGR-1174 to APo and 2017-SGR-1033 to MCa and Spanish Association Against Cancer (AECC, PROYE19040POST_001) to APo and JM; and grants from Instituto de Salud Carlos III (PI13/01728 and PI19/0740) to JM.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study

  • Español-Rego, Marta
  • Fernández-Martos, Carlos
  • Élez, Elena
  • Pedrosa, Leire
  • Rodríguez, Núria
  • Ruiz‑Casado, Ana
  • Pineda, Estela
  • Rodríguez, Núria
  • Cid, Joan
  • Cabezón, Raquel
  • Oliveres, Helena
  • Lozano, Miquel
  • Ginés, Angels
  • García‑Criado, Ángeles
  • Ayuso, Juan Ramón
  • Pagés, Mario
  • Cuatrecasas, Miriam
  • Torres, Ferrán
  • Thomson, Timothy M.
  • Cascante, Marta
  • Benítez-Ribas, Daniel
[Background]: Immune check-point blockade (ICB) has shown clinical beneft in mismatch repair-defcient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-profcient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic efects. [Methods]: This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor efects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efcacy of the combination. The primary end-point was 40% progressionfree survival at 6 months with a 2 Simon Stage. [Results]: A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design frst-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1–5.3 months] and overall survival was 12.2 months [3.2–23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted signifcant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, infammation and oxidative stress pathways. [Conclusions]: The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the frst-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapyinduced tumor vulnerabilities., The study was funded by grants from the FIS PI17/00732 from Instituto de Salud Carlos III, Premi Fi de Residència Emili Letang from Hospital Clínic Barcelona, Plan Nacional de I + D (PID-107139RB-C21 to DB-R and PID2020-115051RB-I00 to MC) and Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD). The study was funded with Grants from Catalan Agency for Management of University and Research Grants (AGAUR) (2014-SGR-474, 2017-SGR-1174 and 2017-SGR-1033), Fundació la Marató de TV3 (201330.10), Instituto de Salud Carlos III (PI13/01728 and PI19/00740) and Fundacion Olga Torres (Modalitat A. 2019/2020) to JM. IMMETCOLS signature is under patent protection (EP21382772.8.) This research was financially supported by GEMCAD and (OR Avelumab was provided) by Merck, S.L.U., Madrid, Spain, an affiliate of Merck KGaA, Darmstadt, Germany, as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: https://doi.org/10.13039/100009945) and Pfizer., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Defining the metabolic signatures associated with human macrophage polarisation

  • Povo-Retana, Adrián
  • Landauro-Vera, Rodrigo
  • Fariñas, Marco
  • Sánchez-García, Sergio
  • Álvarez-Lucena, Carlota
  • Marín, Silvia
  • Cascante, Marta
  • Boscá, Lisardo
Macrophages are essential components of the innate immune system that play both homeostatic roles in healthy organs, and host defence functions against pathogens after tissue injury. To accomplish their physiological role, macrophages display different profiles of gene expression, immune function, and metabolic phenotypes that allow these cells to participate in different steps of the inflammatory reaction, from the initiation to the resolution phase. In addition, significant differences exist in the phenotype of macrophages depending on the tissue in which they are present and on the mammalian species. From a metabolic point of view, macrophages are essentially glycolytic cells; however, their metabolic fluxes are dependent on the functional polarisation of these cells. This metabolic and cellular plasticity offers the possibility to interfere with the activity of macrophages to avoid harmful effects due to persistent activation or the release of molecules that delay tissue recovery after injury., This work has been supported by Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación 10.13039/501100011033 (PID2020-113238RB-I00, PID2020-115051RB-I00 and CPP2021-008392, co-financed by NextGenerationEU’/PRTR), and Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CB16/11/00222) y Enfermedades Hepáticas y Digestivas (CB17/04/00023) from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund ‘A Way to Achieve Europe’); Comunidad de Madrid Programa Biociencias (P2022-BMD-7223); from AGAUR (2021 SGR 00350) and ICREA foundation (ICREA-Academia-2021 to M.C.) of Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity

  • Povo-Retana, Adrián
  • Fariñas, Marco
  • Landauro-Vera, Rodrigo
  • Mojena, Marina
  • Álvarez-Lucena, Carlota
  • Fernández-Moreno, Miguel Ángel
  • Castrillo, Antonio
  • Rosa, Juan V. de la
  • Sánchez-García, Sergio
  • Foguet, Carles
  • Mas, Francesc
  • Marín, Silvia
  • Cascante, Marta
  • Boscá, Lisardo
In recent years, the central role of cell bioenergetics in regulating immune cell function and fate has been recognized, giving rise to the interest in immunometabolism, an area of research focused on the interaction between metabolic regulation and immune function. Thus, early metabolic changes associated with the polarization of macrophages into pro-inflammatory or pro-resolving cells under different stimuli have been characterized. Tumor-associated macrophages are among the most abundant cells in the tumor microenvironment; however, it exists an unmet need to study the effect of chemotherapeutics on macrophage immunometabolism. Here, we use a systems biology approach that integrates transcriptomics and metabolomics to unveil the immunometabolic effects of trabectedin (TRB) and lurbinectedin (LUR), two DNA-binding agents with proven antitumor activity. Our results show that TRB and LUR activate human macrophages toward a pro-inflammatory phenotype by inducing a specific metabolic rewiring program that includes ROS production, changes in the mitochondrial inner membrane potential, increased pentose phosphate pathway, lactate release, tricarboxylic acids (TCA) cycle, serine and methylglyoxal pathways in human macrophages. Glutamine, aspartate, histidine, and proline intracellular levels are also decreased, whereas oxygen consumption is reduced. The observed immunometabolic changes explain additional antitumor activities of these compounds and open new avenues to design therapeutic interventions that specifically target the immunometabolic landscape in the treatment of cancer., This work has been supported by: Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación 10.13039/501100011033 (PID2020-113238RB-I00 and PID2020-115051RB-I00), and Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222) y en Enfermedades hepáticas y digestivas (CB17/04/00023) from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”); Comunidad de Madrid Programa Biociencias (P2022-BMD-7223); from AGAUR (2021 SGR 00350) and ICREA foundation (ICREA-Academia-2021 to MC) of Generalitat de Catalunya; and Spanish Structures of Excellence María de Maeztu program (CEX2021-001202-M)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001202-M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Autonomous metabolic reprogramming and oxidative stress characterize endothelial dysfunction in acute myocardial infarction

  • Zodda, Erika
  • Tura-Ceide, Olga
  • Mills, Nicholas L.
  • Tarragó‐Celada, Josep
  • Carini, Marina
  • Thomson, Timothy M.
  • Cascante, Marta
Compelling evidence has accumulated on the role of oxidative stress on the endothelial cell (EC) dysfunction in acute coronary syndrome. Unveiling the underlying metabolic determinants has been hampered by the scarcity of appropriate cell models to address cell-autonomous mechanisms of EC dysfunction. We have generated endothelial cells derived from thrombectomy specimens from patients affected with acute myocardial infarction (AMI) and conducted phenotypical and metabolic characterizations. AMI-derived endothelial cells (AMIECs) display impaired growth, migration, and tubulogenesis. Metabolically, AMIECs displayed augmented ROS and glutathione intracellular content, with a diminished glucose consumption coupled to high lactate production. In AMIECs, while PFKFB3 protein levels of were downregulated, PFKFB4 levels were upregulated, suggesting a shunting of glycolysis towards the pentose phosphate pathway, supported by upregulation of G6PD. Furthermore, the glutaminolytic enzyme GLS was upregulated in AMIECs, providing an explanation for the increase in glutathione content. Finally, AMIECs displayed a significantly higher mitochondrial membrane potential than control ECs, which, together with high ROS levels, suggests a coupled mitochondrial activity. We suggest that high mitochondrial proton coupling underlies the high production of ROS, balanced by PPP- and glutaminolysis-driven synthesis of glutathione, as a primary, cell-autonomous abnormality driving EC dysfunction in AMI., The project leading to this work has received funding from: The European Commission Horizon 2020 research and innovation program under the MOGLYNET H2020-MSCA-ITN-EJD grant (agreement No 675527); CIBER- Carlos III National Institute of Health, Spain (TT and MCas: CIBEREHD-CB17/04/00023; OTC: CIBERES-CP17/00114); Spanish Ministerio de Economia y Competitividad (MINECO) and Ministerio de Ciencia e Innovación -European Commission FEDER funds—'Una manera de hacer Europa' (TT: PID2019-107139RB-C21 and MCas: PID2020-115051RB-I00); Generalitat de Catalunya-AGAUR (MCas: ICREA Academia Prize 2021, MCas: 2021 SGR00350; TT: 2021 SGR1490); Plataforma Temática Interdisciplinary – Salud Global (TT: SGL2103019); NLM is supported by the British Heart Foundation (RE/18/5/34216, RG/20/10/34966, CH/F/21/90010)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immunometabolic Effect of Nitric Oxide on Human Macrophages Challenged With the SARS-CoV2-Induced Cytokine Storm. A Fluxomic Approach

  • Sánchez-García, Sergio
  • Povo-Retana, Adrián
  • Marín, Silvia
  • Madurga, Sergio
  • Fariñas, Marco
  • Aleixandre, Nuria
  • Castrillo, Antonio
  • Rosa, Juan V. de la
  • Álvarez-Lucena, Carlota
  • Landauro-Vera, Rodrigo
  • Prieto, Patricia
  • Cascante, Marta
  • Boscá, Lisardo
The cytokine storm associated with SARS-CoV-2 infection is one of the most distinctive pathological signatures in COVID-19 patients. Macrophages respond to this pro-inflammatory challenge by reprogramming their functional and metabolic phenotypes. Interestingly, human macrophages fail to express the inducible form of the NO synthase (NOS2) in response to pro-inflammatory activation and, therefore, NO is not synthesized by these cells. The contribution of exogenously added NO, via a chemical NO-donor, on the immunometabolic changes associated with the cytokine storm is investigated. By using metabolic, transcriptomic, and functional assays the effect of NO in human macrophages is evaluated and found specific responses. Moreover, through integrative fluxomic analysis, pathways modified by NO that contribute to the expression of a particular phenotype in human macrophages are identified, which includes a decrease in mitochondrial respiration and TCA with a slight increase in the glycolytic flux. A significant ROS increase and preserved cell viability are observed in the presence of NO, which may ease the inflammatory response and host defense. Also, NO reverses the cytokine storm-induced itaconate accumulation. These changes offer additional clues to understanding the potential crosstalk between NO and the COVID-19 cytokine storm-dependent signaling pathways., This work has been supported by: PID2020-113238RB-I00 and PID2020-115051RB-I00 from MICIN/AEI 13039/501100011033, and Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222) y en Enfermedades Hepáticas y Digestivas (CB17/04/00023) from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”, by the “European Union” and by the “European Union NextGeneration EU/PRTR”); Comunidad de Madrid, Programa Biociencias (S2022-BMD-7223); from AGAUR (2021 SGR 00350 and 2020PANDE00048) of Generalitat de Catalunya (MC); and Spanish Structures of Excellence María de Maeztu program (CEX2021-001202-M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lipoxin A4 levels correlate with severity in a Spanish COVID-19 cohort: potential use of endogenous pro-resolving mediators as biomarkers

  • Sánchez-García, Sergio
  • Jaén, Rafael I.
  • Lozano-Rodríguez, Roberto
  • Avendaño-Ortiz, José
  • Pascual‐Iglesias, Alejandro
  • Hurtado-Navarro, Laura
  • López-Collazo, Eduardo
  • Boscá, Lisardo
  • Prieto, Patricia
[Background]: SARS-CoV-2, the causative virus of the COVID-19 global pandemic, leads to a wide variety of responses among patients. Some of them present a very severe phenotype, while others only experience mild symptoms or are even asymptomatic. This differential prognosis is tightly related to the inflammatory status of the patient. Although WHO declared the end of the emergency, the pandemic caused a great socio-sanitary impact in all countries. Thus, the possible outbreak of new biological diseases in the future makes it necessary to deepen the knowledge of this uncontrolled immune response and look for reliable biomarkers to help us predict its potential health impact. Specialized pro-resolving lipid mediators (SPMs) as lipoxins are endogenous mediators synthesized from arachidonic acid in the resolution stage of any inflammatory process. These lipids have pro-resolving actions in several pathological models, including reducing NF-κB-mediated inflammation, and inducing the antioxidant response through the Nrf-2 pathway. Thus, although a potential relationship has already been suggested between low levels of SPMs and COVID-19 severity, their true role as a predictive biomarker is still unknown., [Methods and results]: In this study, we have analyzed by ELISA the serum levels of lipoxin A4 (LXA4) in a representative Spanish cohort. We found reduced levels in deceased patients when compared to mild or severe patients, concomitant with a decrease in the LXA4 biosynthetic pathway and an increase in its degradation pathway. Furthermore, we have studied the correlation between the levels of this SPM and several pathology indicators, finding a significant correlation between increased LXA4 levels and a better prognosis of the patients., [Conclusion]: We propose to measure systemic LXA4 as a new promising biomarker to predict the survival in patients affected by SARS-CoV-2 and presumably to other viruses that can affect humanity in the future., This work has been supported by: PID2023-148933OB-I00 and PID2020-115051RB-I00 from MICIU/AEI 13039/501100011033; Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222) and CIBERES (CB15/00037), from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”, by the “European Union” and by the “European Union NextGeneration EU/PRTR”); Intramural-CSIC 202320E201 and by Comunidad de Madrid, Programa Biociencias (S2022-BMD-7223), and “Fondos FEDER” to EL-C (PIE15/00065, PI18/00148, PI14/01234, PI21/00869)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells

  • Tarrado‐Castellarnau, Míriam
  • Foguet, Carles
  • Tarragó‐Celada, Josep
  • Palobart, Marc
  • Hernández-Carro, Claudia
  • Perarnau, Jordi
  • Zodda, Erika
  • Polat, Ibrahim H.
  • Marín, Silvia
  • Suarez-Bonnet, Alejandro
  • Lozano, Juan José
  • Yuneva, Mariia
  • Thomson, Timothy M.
  • Cascante, Marta
Several mechanisms of resistance of cancer cells to cyclin-dependent kinase inhibitors (CDKi) have been identified, including the upregulation of metabolic regulators such as glutaminase. However, whether such resistance mechanisms represent optimal targets has not been determined. Here, we have systematically analyzed metabolic reprogramming in colorectal cancer cells exposed to Palbociclib, a CDKi selectively targeting CDK4/6, or Telaglenastat, a selective glutaminase inhibitor. Through multiple approaches, we show that Palbociclib and Telaglenastat elicit complementary metabolic responses and are thus uniquely suited to counter the metabolic reprogramming induced by the reciprocal drug. As such, while Palbociclib induced reduced tumor growth in vivo, and Telaglenastat did not show a significant effect, the drug combination displayed a strong synergistic effect on tumor growth. Likewise, initial responses to Palbociclib were followed by signs of adaptation and resistance, which were prevented by combining Palbociclib with Telaglenastat. In conclusion, combination with Telaglenastat optimally forestalls acquired resistance to Palbociclib in cancer cells., This work was supported by I + D + i projects PID2023-150539OB-I00, PID2020-115051RB-I00, and PID2019-107139RB-C21, funded by MICIU/AEI/10.13039/501100011033/ European Commission FEDER funds “Una manera de hacer Europa”, the Interdisciplinary Platform-Global Health (Plataforma Temática Interdisciplinar-Salud Global, PTI-SG; SGL2103019), the Networked Researched Center on Liver and Digestive Diseases (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, CIBER-EHD; EHD20PI03 and CB17/04/00023), the Catalan Agency for Universities and Research (AGAUR) (2021-SGR-00350 and 2021-SGR-01490), ICREA Foundation (ICREA Academia award granted to M. Cascante) and The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001223), the UK Medical Research Council (FC001223) and the Wellcome Trust (FC001223)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Circulating metabolic markers after surgery identify patients at risk for severe postoperative complications: a prospective cohort study in colorectal cancer

  • Montcusí Ventura, Blanca
  • Madrid-Gambin, Francisco
  • Pozo Mendoza, Óscar J., 1975-
  • Marco, Santiago
  • Marin, Silvia
  • Mayol Girbau, Xavier
  • Pascual, Marta
  • Alonso, Sandra
  • Salvans Ruiz, Silvia
  • Jiménez-Toscano, Marta
  • Cascante Serratosa, Marta
  • Pera Román, Miguel
Background: Early detection of postoperative complications after colorectal cancer (CRC) surgery is associated with improved outcomes. The aim was to investigate early metabolomics signatures capable to detect patients at risk for severe postoperative complications after CRC surgery. Materials and methods: Prospective cohort study of patients undergoing CRC surgery from 2015 to 2018. Plasma samples were collected before and after surgery, and analyzed by mass spectrometry obtaining 188 metabolites and 21 ratios. Postoperative complications were registered with Clavien-Dindo Classification and Comprehensive Complication Index. Results: One hundred forty-six patients were included. Surgery substantially modified metabolome and metabolic changes after surgery were quantitatively associated with the severity of postoperative complications. The strongest positive relationship with both Clavien-Dindo and Comprehensive Complication Index (β=4.09 and 63.05, P <0.001) corresponded to kynurenine/tryptophan, against an inverse relationship with lysophosphatidylcholines (LPCs) and phosphatidylcholines (PCs). Patients with LPC18:2/PCa36:2 below the cut-off 0.084 µM/µM resulted in a sevenfold higher risk of major complications (OR=7.38, 95% CI: 2.82-21.25, P <0.001), while kynurenine/tryptophan above 0.067 µM/µM a ninefold (OR=9.35, 95% CI: 3.03-32.66, P <0.001). Hexadecanoylcarnitine below 0.093 µM displayed a 12-fold higher risk of anastomotic leakage-related complications (OR=11.99, 95% CI: 2.62-80.79, P =0.004). Conclusion: Surgery-induced phospholipids and amino acid dysregulation is associated with the severity of postoperative complications after CRC surgery, including anastomotic leakage-related outcomes. The authors provide quantitative insight on metabolic markers, measuring vulnerability to postoperative morbidity that might help guide early decision-making and improve surgical outcomes. Trial registration: ClinicalTrials.gov NCT02789709., This study was supported by research grant from Instituto de Salud Carlos III (FIS grant PI19/00643) and co-funded by the European Union. FMG was supported by Grant FJC2018-035791-I funded by MCIN/AEI/10.13039/501100011033. SM and MC were supported by Grant PID2020-115051RB-I00 funded by MCIN/AEI/10.13039/501100011033. SM and MC were supported by Grant 2017SGR1033 funded by AGAUR. MC was supported by ‘ICREA Academia’ award funded by ICREA Foundation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients, GEMCAD 1602 study

  • Español-Rego, Marta|||0000-0001-5497-2276
  • Fernández-Martos, Carlos
  • Elez, Elena|||0000-0002-4653-6324
  • Foguet, Carles
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Rodríguez, Nuria
  • Ruiz-casado, Ana
  • Pineda, Estela|||0000-0003-2128-747X
  • Cid, Joan|||0000-0001-5445-4508
  • Cabezón, Raquel
  • Oliveres, Helena|||0000-0003-1801-1181
  • Lozano, Miquel|||0000-0003-2593-833X
  • Ginés, Angels
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Ayuso Colella, Juan Ramón|||0000-0002-5306-6850
  • Pagés, Mario
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Torres, Ferran|||0000-0002-7355-7913
  • Thomson, Timothy
  • Cascante, Marta
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Torres, Ferran|||0000-0002-7355-7913
Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects. This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage. A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1-5.3 months] and overall survival was 12.2 months [3.2-23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways. The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities. The online version contains supplementary material available at 10.1007/s00262-022-03283-5.